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Abstract
Background Fear-potentiated startle has been suggested as
a translational model for evaluating efficacy of anxiolytic
compounds in humans. Several known anxiolytic com-
pounds have been tested as well as several putative
anxiolytics. Because results of these studies have been
equivocal, the aim of the present study was to examine
another pharmacological permutation of the human poten-
tiated startle model by comparing two anxiolytic agents to a
non-anxiolytic sedative and placebo.
Methods Twenty healthy volunteers participated in a double-
blind, placebo-controlled, cross-over study with four sessions
in which they received single doses of the anxiolytics
alprazolam (1 mg) and pregabalin (200 mg), as well as
diphenhydramine(50mg)asanon-anxiolyticsedativecontrol
and placebo. The design included a cued shock condition that
presumably evokes fear and an unpredictable shock context
condition presumably evoking anxiety.
Results None of the treatments reliably reduced either fear-
or anxiety-potentiated startle. Alprazolam and diphenhy-
dramine reduced overall baseline startle. Alprazolam was
found to only affect contextual anxiety in a statistical
significant way after two subjects who failed to show a
contextual anxiety effect in the placebo condition were
excluded from the analysis. Pregabalin did not significantly
affect any of the physiological measures.
Discussion The negative findings from this study are
discussed in terms of methodological differences between
designs and in variability of startle both between and within
study participants.
Conclusion Even though fear-potentiated startle may be
used to translate preclinical evidence to human populations,
methodological issues still hamper the application of this
model to early screening of putative anxiolytic drugs.
Keywords Fear.Anxiety.Fear-potentiatedstartle.
Humanmodel.Alprazolam.Pregabalin
Introduction
Fear-potentiated startle (FPS) has been suggested as a
promising translational tool for screening putative anxio-
lytic substances (Grillon 2008). Nevertheless, pharmaco-
logical validation of this model has yielded mixed results.
FPS was shown to be reduced with putative anxiolytic
substances such as the glutamatergic substance LY354740
(Grillon et al. 2003) and testosterone (Hermans et al. 2006).
An acute dose of citalopram exacerbated FPS, in line with
initial anxiogenic effects observed in the clinic (Grillon et
al. 2007). On the other hand, not all validation studies with
a “golden standard” in anxiolytics, benzodiazepines, were
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Bern, Switzerlandsuccessful. The first demonstration of the effects of a
benzodiazepine on potentiated startle was in an emotion
induction model using affective pictures (Patrick et al.
1996). However, in order to stay close to the original
animal models (Davis et al. 1993), most attempts to validate
human FPS with benzodiazepines have focused on versions
of the fear-potentiated startle model that use threat of
electric shocks (Grillon et al. 1993; Grillon et al. 1991).
Bitsios et al. (1999) were the first to validate a threat of
shock FPS model with the benzodiazepine diazepam. In
this model, threat of shock was alternated with intervals of
safe and communicated by applying and removing the
shock electrodes. Startle potentiation in the threat interval
as compared to the safe intervals was significantly reduced
by administration of 10 mg but not 5 mg of diazepam. This
model has also been proven successful with lorazepam
(2 mg, not 1 mg; Graham et al. 2005). In the model
originally introduced by Grillon et al. (1993), Riba and
colleagues reported no effect of the benzodiazepine
lorazepam (4 mg, even though baseline startle was affected
substantially; Riba et al. 1999) and a decrease in FPS after
administration of 1 mg of the benzodiazepine alprazolam
(not 0.25 or 0.5 mg; Riba et al. 2001).
Earlier studies showed that the benzodiazepines oxazepam
(15 and 30 mg) and diazepam (4, 10 and 15 mg) were not
effective in reducing FPS in three different experiments (Baas
et al. 2002a). Several factors were suggested to contribute to
these conflicting results, the most important one being the
exact kind of fear or anxiety responses evoked. Sensitivity of
baseline startle in the context of a threat experiment to
benzodiazepines suggested that perhaps contextual anxiety is
sensitive to benzodiazepines, but cued fear is not (Baas et al.
2002a;G r i l l o n2002; Grillon and Baas 2003). Indeed, the
manipulations validated by Bitsios et al. (1999)a n dG r a h a m
et al. (2005) and arguably also by Riba et al. (2001)h a v e
features of a context manipulation and thus may be assumed
to cause a contextual anxiety response (Baas et al. 2002a;
Grillon et al. 2006). On the other hand, results from a
conditioning study showed that diazepam does not suppress
the expression of a conditioned (i.e., cued) fear-potentiated
startle response (Scaife et al. 2005). Therefore, even though
not all permutations of the threat of shock FPS model were
validated successfully, models that focus on contextual
anxiety should lead to more consistent results (Grillon 2008).
In order to study both contextual anxiety and cued fear, a
new threat of shock design was developed that contained
both cued fear in a predictable shock condition and
contextual anxiety evoked by an unpredictable shock
condition (Grillon et al. 2004). This model was validated
according to the hypotheses: While contextual anxiety was
affected by 1 mg alprazolam, cued fear was not (Grillon et
al. 2006). This study also included diphenhydramine as
non-anxiolytic sedative control and showed that this
compound reduced baseline startle to the same extent as
alprazolam 1 mg while not having the specific effect on
contextual fear. These results increased the evidence that
especially contextual fear is influenced by benzodiazepine
anxiolytics and that this effect cannot be solely attributed to
sedation (Grillon and Baas 2003; Grillon and Baas 2002).
The present study aimed at extending the general
validity of these results. The first aim was to replicate the
dissociation between benzodiazepine effects on cued and
contextual fear in another laboratory. The second aim was
to extend the validation to an anxiolytic substance with
another mechanism of action as benzodiazepines. The study
included treatments with alprazolam and pregabalin as
registered anxiolytics and diphenhydramine as a non-
anxiolytic sedative control in 20 healthy volunteers.
Pregabalin is registered as an anxiolytic substance for
generalized anxiety disorder. Based on the hypothesized
features that contextual anxiety and generalized anxiety
share, a similar profile of efficacy as benzodiazepines was
expected for pregabalin. Diphenhydramine was included as
a non-anxiolytic sedative control. Doses were chosen based
on a prior study in which alprazolam 1 mg had significant
effects in the FPS paradigm, and diphenhydramine 50 mg
produced sedative effects similar to alprazolam 1 mg
(Grillon et al. 2006). The pregabalin dose was chosen
based on anxiolytic efficacy and similar expected levels of
sedation.
Methods
Site
The study was implemented at the Centre for Human Drug
Research in Leiden, the Netherlands.
Subjects
Subjects were recruited from the community by means of
paper advertisements. Forty subjects provided informed
consent and underwent a medical screening. Eight subjects
were found not eligible for the study: Four subjects
displayed reduced startle reactivity at screening, defined
as no discernable response in at least three out of the 12
startle stimuli presented, and four subjects were excluded
for medical reasons. Four subjects withdrew consent after
screening. Twenty-four subjects participated (14 men, ten
women) in the study, of whom 20 completed the study.
Final sample characteristics were ten men and ten women,
with a mean (SD) age of 22.4 (4.2) years and a Spielberger
trait anxiety score of 31.8 (7.3). The study was performed
according to ICH/GCP guidelines. The medical ethics
committee of Leiden University Medical Center approved
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Treatments
The study consisted of a double-blind full cross-over design
with three active treatments (alprazolam 1 mg, pregabalin
200 mg, and diphenhydramine 50 mg) and placebo.
Alprazolam is a benzodiazepine registered for the treatment
of anxiety disorder. Pregabalin (Lyrica®) is a relatively new
compound registered for general anxiety disorder. It is
supposed to modulate neuronal firing through binding to an
auxiliary subunit (α2-δ) of voltage dependent calcium
channels (Stahl 2004). Diphenhydramine is a H1-
antagonist with sedating but no documented primary
anxiolytic properties upon acute treatment. All drugs were
administered orally in identical capsules. Placebo consisted
of an identical capsule containing no active ingredients. The
active treatments alprazolam and pregabalin reach peak
plasma concentrations around 1 h after dosing (Garzone
and Kroboth 1989; Zareba 2005). Diphenhydramine rea-
ches peak plasma concentration somewhat later at 2.3 h
(Blyden et al. 1986), but sedative side effects as reflected in
depressing effects on baseline startle are comparable to the
effects of 1 mg alprazolam when starting the FPS test 1 h
after dosing (Grillon et al. 2006). Elimination half lives of
alprazolam, pregabalin, and diphenhydramine are 9.5–12,
6, and 4 h, respectively (Garzone and Kroboth 1989;
Zareba 2005; Paton and Webster 1985). The order of the
treatments of placebo (Pla), alprazolam (Alp), diphenhy-
dramine (Dip), and pregabalin (Prg) was defined by a
Williams Latin Square design (sequence 1: Pla, Prg, A1p,
Dip; 2: Prg, Dip, Pla, A1p; 3: A1p, Pla, Dip, Prg; 4: Dip,
A1p, Prg, Pla). Each subject was randomly assigned to one
of the four sequences. Subjects who dropped out were
replaced with another subject who received the same
sequence. All four study days were identical and separated
by washout periods of a week, with incidental deviations
but guaranteeing a washout period of at least 3 days. After a
standard breakfast 2 h before ingestion, baseline assess-
ments were made, followed by administration of the study
medication. The duration of the FPS paradigm was
approximately 45 min and was performed between 1 and
2 h after dosing.
Stimuli and apparatus
Shock reinforcements were delivered through two disk
electrodes located on the inside of the subjects’ forearms
using a Digitimer DS7A constant current stimulator (Digi-
timer, Hertfordshire, England). Stimulation consisted of short
(750 ms) trains of 2-ms pulses delivered at 20 Hz. A shock
workup procedure was performed to individually set the level
of shock used in the study. This workup consisted of three to
five sample shocks, after each of which subjects rated how
annoying/painful they found the preceding shock on a five-
point scale. The level used in the study was the level at which
a rating of 4 was achieved corresponding to “quite a bit
painful/annoying”. The startle reflex was evoked by bursts of
white noise presented through headphones with 50-ms
duration and an intensity of 105 dB(A). Task conditions as
well as visual analog scales (VAS) were presented on a
computer screen by automated scripts ran in the software
package Presentation (Neurobehavioral Systems).
To assess eye blink startle response, EMG measurements
were made from two electrodes on the lower orbicularis
oculi muscle with a Grass Instruments system (Grass
Technologies, West Warwick, USA). Skin conductance
was recorded with a Grass Instruments skin conductance
unit.
Subjects were asked to rate their level of emotional
responding on a VAS at several times during the FPS
procedure as an additional measure of emotional respond-
ing induced by the different task conditions. Included in
these rating scales were questions about level of fear during
all task conditions, i.e., during neutral, predictable, and
unpredictable conditions, and in absence and presence of
the visual cues. To assess levels of anxiety throughout the
study day, subjects completed the state portion of the
State-Trait Anxiety Inventory (STAI-DY1, Spielberger
1972) every hour. The trait anxiety levels reported on the
screening day with the trait portion of the STAI are
included in this paper.
Experimental procedure
The FPS task was included in a larger protocol assessing
multiple dimensions of sedation as well as state anxiety and
blood samples for pharmacokinetic/pharmacodynamic anal-
ysis at regular time intervals throughout the test day. This
included several tests of central nervous system functioning
(body sway, VAS scales of sedation (Bond and Lader
1974), adaptive tracking, saccadic eye movements, smooth
pursuit eye movements). These data will be reported
elsewhere. Main outcome parameter of the FPS task was
startle magnitude across conditions, but skin conductance
and subjective VAS ratings of fear and calmness were taken
as additional measures of anxiety, in addition to a VAS
rating of sedation (alertness).
The FPS procedure started with placement of electrodes
on the orbicularis oculi muscle for startle measurement and
on the palmar side of the left index and middle fingers for
skin conductance recording. Each test session began with a
series of nine startle stimuli presented with average
intervals of 16 s. After this, the shock electrodes were
placed, and instructions concerning the FPS experiment
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contexts in which instructions regarding possible shock
administration varied (Grillon et al. 2004, 2006). These
contexts were signaled by a written text displayed on a
computer monitor: “No shock” (Neutral context, N);
“Shock only during cue” (Predictable context, P); and
“Shock at any time” (Unpredictable context, U). In each
context, cues were presented, e.g., red square for N, blue
circle for P, and green triangle for U (assignment of stimuli
to contexts counterbalanced between subjects). These cues
were only predictive of a possible shock in the P context.
Duration of contexts was 90–100 s, during which the verbal
instructions concerning shock delivery remained on the
screen and four cues were presented at regular time
intervals with 8-s duration. Startle responding was assessed
during all experimental conditions, i.e., during the presen-
tation of these cues, as well as in their absence, which
constituted the measure for contextual responding. Subjec-
tive ratings were also taken to differentiate between
contexts and conditions of cue present and absent, but skin
conductance responses are measured only in response to the
discrete cues and to the onset of the context because a
continuous measure of responding during the context
cannot be derived.
The FPS test consisted of two blocks with the following
predeterminedordersofcontexts:(1)P-N-U-N-U-N-Pand(2)
U-N-P-N-P-N-U. Each session consisted of both blocks, with
the order of these two blocks counterbalanced across subjects.
During each context, three startle probes were delivered in the
absence and three in the presence of a cue, hence six per
experimental condition per block and 12 in total across the
experiment. Intervals between startle probes varied between
12 and 18 s (16 s on average). In each block, one of the two
occurrences of the shock (P and U) contexts contained one
shock reinforcement, and the other occurrence contained two
shock reinforcements. Shock reinforcements during P con-
texts always coincided with a cue, hence predictably, while
reinforcements during U were administered in absence of the
cue (statistically, some would coincide with a cue if
administered randomly but these were excluded in order to
prevent an association being made between the cue in the U
context and the shocks). A total of 12 shocks were
administered during each FPS test session. Orders of startle
trials across experimental conditions and shock reinforce-
ments were counterbalanced between blocks, sessions, and
subjects. Each block began with three startle probes for
habituation. After each block, subjective ratings on levels of
fear specified for all experimental conditions were collected
using computerized VAS scales [anchors 0=not fearful, 100=
very fearful], as well as ratings on subjective state at that time,
including fearfulness [same anchors], sedation [anchors 0=
not alert, 100=very alert], and calmness [anchors 0=not at all
calm, 100=very calm]. In addition, the subjective aversive-
ness of shocks [anchors 0=not annoying, 100=very annoy-
ing] and startle probes [anchors 0=very uncomfortable, 100=
very comfortable] was evaluated.
Data analyses
Analysis of the EMG signal was carried out in Brain Vision
Analyzer software, and trials containing artifacts were
removed according to established procedures (Blumenthal
et al. 2005; Böcker et al. 2004; Mol et al. 2007). Startle
magnitude was defined as the peak of the integrated signal
in the period between 0 and 125 ms after presentation of the
acoustic startle probe. For each participant, averages per
condition across trials were calculated. There were two
subjects who displayed relatively low startle magnitudes
even after passing the baseline startle criterion at screening.
Additional analyses were run excluding these subjects,
which did not change any of the conclusions.
Skin conductance responses were quantified by scoring
the peak response between 0.5 and 5 s after stimulus onset.
Before statistical analysis, SCR data were normalized using
a log transformation following Grillon et al. (2006).
All statistical analyses were repeated measures analyses
of variance in SPSS 14 for Windows on averaged data per
session and condition. Univariate (within-subjects) tests
were reported, while Greenhouse Geisser epsilon correc-
tions were applied for violations of the assumption of
sphericity. In some cases, the multivariate tests yielded
more power for the interactions with Drug, and in those
cases, the multivariate tests are reported as well. Tests of
planned primary contrasts using univariate contrasts for
each drug condition against placebo were included and
were reported in case these reached (p<0.05) or approached
(<0.10) significance.
To test drug effects on FPS and VAS to explicit threat
cues during the predictable shock condition, a Cue (Cue
absent, Cue present) × Drug (4) ANOVAwas employed. To
test drug effects on FPS during the unpredictable shock
context, a Context (Neutral context, Unpredictable context) ×
Drug (4) ANOVA was employed. An additional analysis on
normalized data was included to assess the effects of reducing
between-subjects variance caused by differences in baseline
startle between subjects. Therefore, FPS analyses were
repeated on T scores calculated across all measurements per
subject.
SCR are not evoked in absence of stimulation during the
contexts; therefore, SCR to the fear cue in the predictable
condition was analyzed with SCR to the cue in the neutral
condition as a control, with factors Cue (Cue in neutral
context, Cue in predictable shock context) × Drug (4). SCR
increase to the onsets of the unpredictable context was
analyzed with a Context (Neutral, Unpredictable) × Drug
(4) ANOVA.
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on baseline startle (cf. Baas et al. 2002a) were assessed with
correlation and regression analyses. For this purpose,
average measures were taken across all conditions for both
startle magnitude and the ratings of fearfulness during these
conditions, and difference scores were taken based on the
value during each of the drug conditions minus that value
during the placebo condition. Along the same lines,
alternative measures were derived for just the neutral
conditions. The average score on the VAS alertness scale
taken after each of the two blocks was employed as
measure of sedation. In addition, to more generally explore
other factors possibly contributing to differences in baseline
startle, correlation analyses were done between these two
measures of baseline startle (calculated based on all trials or
based on just the trials during the neutral condition) and
alertness and the two different measures of the VAS
fearfulness ratings (calculated based on all conditions or
based on just the neutral condition), plus the additional
subjective ratings of subjective state right after each of the
blocks (fearfulness and calmness, averaged across the
measures per block) and two measures of the Spielberger
State Anxiety score taken just prior and just after the FPS
test. Of these, exploratory correlational analyses summaries
were reported, and only significant correlations were
highlighted.
Results
FPS
Startle magnitude was highly significantly increased in the
predictable condition during the presence compared to the
absence of the cue that predicted a shock (see Fig. 1,m a i n
effect of Cue, F(1,19;GGε=1)=24.4, p<0.001). Effects on
overall startle magnitude were reflected in a main effect of
Drug (F(3,57;GGε=0.80)=7.4, p<0.001). Follow-up con-
trasts assessing differences from the placebo condition
indicated significant reductions in overall startle magnitude
by alprazolam (F(1,19;GGε=1)=10.1, p<0.01) and diphen-
hydramine (F(1,19;GGε=1)=9.6, p<0.01), but not pregaba-
lin treatment (F(1,19;GGε=1)=0.0, NS). There was no
significant effect of any of the active treatments on FPS
(interaction Cue × Drug, F(3,57;GGε=0.84)=0.5, NS).
There was also a highly significant effect of the context
manipulation on startle magnitudes (Fig. 2, main effect of
Context F(1,19;GGε=1)=24.3, p<0.001). Similar to the
startle data from the specific cue condition, both alprazolam
and diphenhydramine significantly reduced overall startle
magnitude (main effect Drug F(3,57;GGε=0.84)=8.0, p<
0.001; significant contrasts between alprazolam and place-
bo F(1,19;GGε=1)=13.6, p<0.005, diphenhydramine and
placebo F(1,19;GGε=1)=12.2, p<0.005, pregabalin and
placebo F(1,19;GGε=1)=0.2, NS). However, the expected
interaction effect between context and treatment was not
significant (F(3,57;GGε=0.77)=1.4, NS).
In an additional post hoc analyses, two subjects were found
to display very small potentiation (context U–context N<
1.5 µV, which corresponds to <3.1% of their startle level
during context N), and two subjects even showed the opposite
of context potentiation of startle under placebo treatment (one
subject scored −10.0 µV (−4.6%), the other −11.2 µV
(−5.3%)). Analyses of the data excluding the latter two
subjects (N=18, see hatched bars in Fig. 2) revealed that the
Drug × Context interaction, including all four levels of the
factor Drug did not reach significance in the univariate tests
(F(3,51)=1.7, p=0.19, while a trend toward significance was
observed in the multivariate test, F(3,15)=3.1, p=0.06). Also,
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Fig. 1 Startle magnitudes in the predictable context reflecting cued
FPS. Error bars are standard error of the mean. Pla placebo, Alp
alprazolam, Dip diphenhydramine, Prg pregabalin
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Fig. 2 Startle magnitudes in the unpredictable versus neutral contexts
reflecting context FPS. Error bars are standard error of the mean. Pla
placebo, Alp alprazolam, Dip diphenhydramine, Prg pregabalin
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interaction of Drug × Context was significant (F(1,17)=5.2,
p<0.05), whereas the effects of diphenhydramine (F(1,17)=
2.0, NS) and pregabalin (F(1,17)=0.0, NS) were not.
Analyses on T scores revealed highly significant effects of
cued FPS (F(1,19;GGε=1)=49.6, p<0.001) and context FPS
(F(1,19;GGε=1)=43.5,p<0.001) on startle magnitude, which
were not affected by Drug (Cue × Drug F(3,57;GGε=0.84)=
0.4, NS; Context × Drug F(3,57;GGε=0.85)=0.1, NS).
VAS reports of subjective fear per condition
There was a very significant main effect of presence of the
threat cue in the predictable condition on rating of fearfulness
(F(1,19;GGε=1)=27.9, p<0.001, see Table 1)a n dam a i n
effect of drug on overall reported fearfulness during the
predictable shock condition (F(3,57;GGε=0.90)=4.9, p<
0.01). The effect of drug is due to reduced fearfulness in the
alprazolam condition with respect to placebo (F(1,19;GGε=
1)=10.7, p<0.005); the other treatments did not reach
significance (F values for diphenhydramine and pregabalin
are 0.2 and 1.4, respectively). The interaction between the
effects of the fear induction and drug condition was not
significant (F(3,57;GGε=0.82)=1.4, NS).
The difference in VAS fearfulness data during the
unpredictable and neutral contexts (Table 1) corresponds
to contextual FPS. There was a significant main effect of
threat context on rating of fearfulness (F(1,19;GGε=1)=
57.1, p<0.001) and a main effect of drug on overall
reported fearfulness during the unpredictable shock condi-
tion (F(3,57;GGε=0.78)=3.5, p<0.05). The effect of drug
was due to reduced fearfulness in the alprazolam condition
(follow-up contrast comparing alprazolam to placebo: F
(1,19;GGε=1)=5.8, p<0.05); the other treatments do not
reach significance (F values for the comparisons of
diphenhydramine and pregabalin to placebo are 0.1 and
1.6, respectively). The interaction between the threat
manipulation and drug condition did not reach significance
(F(3,57;GGε=0.96)=1.8, NS), although the condition
effect tested specifically between placebo and alprazolam
closely approached significance (F(1,19;GGε=1)=4.4, p=
0.05, F values for diphenhydramine and pregabalin were,
respectively, 2.8 and 0.2, NS). The two subjects who
displayed a negative context effect with startle also showed
a small effect on their subjective ratings (<3 out of 100
points), but there were four other subjects with such a small
difference in subjective fear reports between the neutral and
unpredictable context. The exclusion of these two subjects
yielded very similar results.
VAS reports on overall fear, alertness/calmness, and shock/
probe evaluation
Table 2 contains the VAS data on subjective ratings on
fearfulness, alertness, calmness, and shock and probe
evaluation taken after each of the two runs of the FPS
procedure (averaged across runs). After runs of the FPS
experiment, subjects reported feeling less anxious under
pregabalin and less alert under alprazolam and diphen-
hydramine. All drug treatments increased subjective
ratings of calmness slightly, but not significantly. Only
alprazolam had a significant effect on evaluation of the
shock.
Regression and correlation analysis of drug effects
on baseline startle and subjective fear/sedation
The regression analysis indicated that differences in VAS
fearfulness and sedation predicted drug-induced differ-
ences in baseline startle for none of the drugs (averaged
across all conditions all values for F(2,17)<1.3, NS).
When including only the neutral conditions, which may
constitute a purer assessment of baseline state, the
prediction for alprazolam approached significance (F
(2,17)=3.1, p=0.07; individual beta’s: fearfulness beta=
0.57, t=2.5, p<0.05, alertness beta=−0.31, t=−1.3, NS).
Table 1 VAS ratings of subjective fear per condition
Predictable context Unpredictable shock context versus neutral context
Cue absent Cue present Cue fear potentiation
(difference)
Neutral
context
Unpredictable shock
context
Context fear potentiation
(difference)
Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM
Pla 32.45 4.99 56.75 5.94 24.30 4.92 14.38 3.73 54.63 5.36 40.25 5.49
Alp 23.15 4.64 42.15 5.66 19.00 4.08 11.23 2.46 43.13 5.28 31.90 4.85
Dip 32.15 5.69 53.95 5.96 21.80 4.95 19.23 3.48 52.35 5.70 33.13 5.05
Prg 27.35 5.62 53.85 6.38 26.50 5.63 10.90 3.19 48.90 5.74 38.00 6.02
SEM standard error of the mean, Pla placebo, Alp alprazolam, Dip diphenhydramine, Prg pregabalin
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remained nonsignificant (values for F(2,17)<1.5, NS).
As suggested by the marginal findings with the
regression analyses, exploratory analyses found few
correlations between subjective effects and effects of
drugs on baseline startle. For alprazolam against placebo,
none of the correlations reached statistical significance
(−0.21<all Pearson r correlations <0.44, all p values >0.05).
A marginally significant correlation was found between the
VAS fear measures and baseline startle during the
neutral condition (Pearson r=0.44, p=0.05). For diphen-
hydramine against placebo, there were also no significant
correlations (−0.32<all Pearson r correlations <0.35, all p
values >0.13). For pregabalin against placebo, there were
some significant correlations (−0.30<all Pearson r corre-
lations <0.56, several p values <0.05). These concerned
the correlations between differences in baseline startle and
the state anxiety score taken after the FPS procedure at 1 h
45 min. This state anxiety measure correlated with
baseline startle regardless of whether all trials were
included in the baseline average (Pearson r=0.56, p<
0.05) or just the trials in the neutral condition (Pearson r=
0.53, p<0.05). This indicates a correlation between
reduced state anxiety and baseline startle under the
influence of pregabalin, which may be interpreted as
indicative of an anxiolytic effect.
Skin conductance
There was a highly significant effect of context on the SCR
response to the cues in the predictable versus neutral
condition (F(1,19;GGε=1)=25.1, p<0.001, see Table 3). In
contrast to the drug effect on overall startle magnitude,
there was no main effect of treatment on SCR responses (F
(3,57;GGε=0.95)=1.3, NS). Like startle, the effect of threat
condition on SCR was not significantly affected by
treatment (interaction between threat condition and treat-
ment, F(3,57;GGε=0.85)=1.1, NS).
The onset of the unpredictable context evoked a SCR that
was significantly larger than the SCR to the onset of the
neutral context (F(1,19;GGε=1)=39.0, p<0.001). As with
the SCRs to the cues in the neutral and predictable
conditions, there was no main effect of treatment on SCR
to the onsets of the neutral and unpredictable contexts (F
(3,57;GGε=0.84)=0.5, NS). The effect of threat condition
(unpredictable minus neutral context) was again not signif-
Table 3 SCR magnitudes
Cues in the neutral and predictable shock contexts Onsets of the neutral and unpredictable shock contexts
Neutral cue Predictable
cue
Cue fear potentiation
(difference)
Neutral
context
Unpredictable shock
context
Context fear potentiation
(difference)
Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM
Pla 0.053 0.008 0.160 0.023 0.107 0.018 0.072 0.019 0.311 0.041 0.239 0.045
Alp 0.072 0.014 0.155 0.034 0.083 0.028 0.101 0.028 0.234 0.052 0.133 0.052
Dip 0.056 0.008 0.129 0.022 0.073 0.120 0.076 0.015 0.243 0.045 0.167 0.041
Prg 0.073 0.011 0.176 0.031 0.103 0.024 0.071 0.020 0.298 0.045 0.227 0.039
SEM standard error of the mean, Pla placebo, Alp alprazolam, Dip diphenhydramine, Prg pregabalin
Table 2 Mean (SEM) VAS rating of overall fearfulness, alertness, calmness, aversiveness of shock, and probe
Placebo Alprazolam Diphenhydramine Pregabalin Main effect Drug
Fearful 34.2 (4.2) 29.9 (3.9) 26.3 (3.9) 24.1 (4.2) F(3,57;GGε=0.77)=2.5, p=0.08
a
Alert 51.7 (3.7) 36.1 (3.3) 41.9 (3.5) 46.5 (3.8) F(3,57;GGε=0.81)=6.4, p<0.005
b
Calm 56.9 (4.1) 64.9 (4.0) 64.6 (3.8) 65.1 (4.0) F(3,57;GGε=0.78)=2.2, NS
Shock 52.7 (3.8) 41.0 (5.4) 50.6 (4.3) 46.0 (4.6) F(3,57;GGε=0.83)=3.9, p<0.05
c
Probe 36.4 (3.4) 38.8 (3.7) 37.7 (2.3) 36.8 (2.8) F(3,57;GGε=0.83)=0.2, NS
SEM standard error of the mean, NS not significant
aAlp–Pla F(1,19)=1.3, NS; Dip–Pla F(1,19)=2.8, NS; Prg–Pla F(1,19)=4.5, p<0.05
bAlp–Pla F(1,19)=14.1, p<0.001; Dip–Pla F(1,19)=5.2, p<0.05; Prg–Pla F(1,19)=1.5, NS
cAlp–Pla F(1,19)=7.0, p<0.05; Dip–Pla F(1,19)=0.3, NS; Prg–Pla F(1,19)=2.8, NS
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condition and treatment, F(3,57;GGε=0.85)=1.8, NS).
Discussion
This study replicates earlier findings (Grillon et al. 2006)
that alprazolam and diphenhydramine do not affect cue-
specific FPS and extends these results in showing that
pregabalin did also not affect FPS in reaction to a specific
cue. In addition, we observed significant effects of
alprazolam and diphenhydramine but not pregabalin on
baseline startle. However, this study did not replicate the
effect of alprazolam on context-potentiated startle found in
the study by Grillon et al. (2006), thereby adding to the
mixed results on pharmacological validation of the FPS
reviewed in the “Introduction” section. These mixed results
could be ground for disqualifying the FPS model as a
screening tool for anxiolytic drugs. However, the FPS
model offers the unique opportunity for direct translation
from animals to humans (Grillon 2008). Even though
pharmacological validation of the FPS model has not
proven straightforward, there is no other human experi-
mental model for anxiety available that has proven more
successful (reviewed below). Therefore, finding the set of
parameters that allows for robust (i.e., repeated) pharmaco-
logical validation of this model remains worthwhile.
What explanations may be possible for our unexpected
null result? First, the lack of significant effects of
alprazolam on context-specific FPS could be a false
negative. Second, the positive results found by Grillon
could have been due to chance. This is however unlikely
given positive results in various other studies (Bitsios et al.
1999; Graham et al. 2005; Riba et al. 2001). Third, the
different results could be explained by methodological
dissimilarities between these studies in participants, exper-
imental parameters, and measurements. Sensitivity of
experimental models to varying parameters is not unprec-
edented (e.g., Davis et al. 1990), and these difficulties can
be overcome if the important parameters are understood. In
this case, it is important to understand which experimental
variations make the difference between whether or not an
anxiolytic effect of benzodiazepines in the human anxiety
model based on fear-potentiated startle is observed.
The design of the present study replicated that of
Grillon et al. (2006). However, comparison of the present
study (parameters listed first) and the alprazolam study of
Grillon et al. (2006, parameters listed second) revealed
some minor differences between the methodologies used.
The subject samples were comparable with similar age
(22.4±4.2 versus 23.0±4.7) and levels of trait anxiety
(31.8±7.3 versus 28.2±4.8), but our study included
r e l a t i v e l ym o r em e n( t e nm e n ,t e nw o m e nv e r s u sf i v e
men, 11 women). However, including Gender as a factor
in the test for drug effects of context FPS did not change
any of the conclusions (all interactions with and main
effect of Gender F< 1 ,N S ) .T h ep a r a m e t e r st h a tw e r e
different in the stimulation protocol were the number of
shock reinforcements (1 or 2 per condition versus 1), the
exact startle noise intensity and duration (105 dB(A),
50 ms versus 103 dB(A), 40 ms), duration of time
intervals between subsequent startle probes (12–20 s
versus 18–25 s), duration of the contexts (90–100 s versus
150 s), and timing of shocks in the unpredictable context
(variable versus 7 or 10 s after cue offset).
Regardless of these differences, VAS rating scale data of
subjective anxiety induced by the unpredictable versus the
neutral context was comparable (4.0 versus 3.8). Baseline
startle magnitudes in absolute values were quite different,
probably reflecting minor differences in preprocessing such
as differences in smoothing factor (baseline startle under
placebo in the neutral context 60.8±8.8µV versus 38.4±
10.8 µV). Therefore, effects of cued fear and contextual
anxiety on absolute startle levels differ. However, the size
of cued FPS was remarkably similar when expressed in
percentage increase (startle magnitude in predictable con-
text without cue 69.2 µV and with cue 85.5 µV, difference
16.3 µV or 24% versus 47.2 µV and 57.9 µV, difference
10.7 µVor 23%). The size of contextual FPS was larger in
the study of Grillon et al. when expressed in percentage
potentiation (startle magnitude in neutral context 60.8 µV
and unpredictable 78.8 µV, difference 18.0 µV or 30%
versus 38.4 µV and 53.6 µV, difference 15.2 µV or 40%).
Any of the differences between the protocols could
theoretically account for the difference in results. For
example, duration of the conditions has been suggested as
an important factor in the differentiation between cued and
contextual responses (Walker et al. 2003), but it seems
unlikely that the difference between 1.5 and 2.5 min would
be crucial. A difference that may be of importance is the
interval between subsequent startle probes, which was
notably shorter in the present study compared to Grillon
et al. (2006). Shortening these intervals does not abolish
fear potentiation effects of cues (present results and Baas et
al. 2002a, b) or contexts (present results and Böcker et al.
2004). Also, shortening these intervals does not affect all
drug effects on startle negatively: In contrast to Grillon et
al. (2006), who found no significant overall depressing
effects of either benzodiazepine or diphenhydramine treat-
ment, both substances markedly reduced baseline startle in
the present study. However, even though changes in state
anxiety may contribute importantly to an overall reducing
effect of drug on startle suggestive of an anxiolytic effect
(see Baas et al. 2002a), replication of this result was only
marginally significant for alprazolam, and interpretation as
anxiolysis is not applicable to diphenhydramine. Shorter
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effects by allowing less recovery between trials, which
might contribute to the sensitivity of baseline startle to the
effects of drugs. Hypothetically, the difference between
studies in sensitivity of baseline startle to drug treatments
may be related to the differential sensitivity of the context
potentiation effect to drug treatments observed. Of interest
in this regard may be that while in Grillon et al. (2006)
baseline startle was unaffected by drug, the context poten-
tiation effect was relatively large. Summarizing, the theoret-
ical possibility exists that shorter inter startle intervals
influence sensitivity of startle modulation to benzodiaze-
pines and possibly also context, which may be related to
reduced sensitivity of context effects to benzodiazepines.
What may be promising is the finding that exclusion of
two subjects who displayed a negative contextual anxiety
effect under the placebo condition (as indicated by more
startle reactivity during the neutral than during the
unpredictable context) yielded a significant specific contrast
with alprazolam. In the study by Grillon et al., there were
several subjects who scored close to zero, but none who
displayed a negative context effect, as the two observed in
this study (not reported in Grillon et al. 2006; data were
kindly provided by C. Grillon for further analyses).
Nevertheless, high variability of startle results between
sessions within subjects and between subjects is a more
general problem that is not easily corrected by excluding
subjects who fail to display the expected behavior under
placebo. In future studies, a baseline measurement as part
of the screening procedure to assess whether each subject
displays the expected fear and anxiety reactions prior to
being exposed to a drug treatment would be advisable,
though this would not prevent variability in behavior within
subjects across sessions.
An additional approach to reduce between-subjects
variance caused by rather extreme differences in baseline
startle between subjects is calculating z or T scores across
all measurements per subject. The analyses on T scores did
not lead to a different conclusion in the present study.
Nevertheless, the amount of variance between subjects and
measurements within subjects observed in this study could
be part of the explanation for the lack of drug effects. In our
previous work, even though the drug manipulations did not
affect FPS significantly, variation in baseline startle
between drug conditions correlated significantly with
differences in state anxiety and sedation as a result of drug
administration (Baas et al. 2002a). For the alprazolam
treatment in the present study, some of the drug effects on
baseline startle may be explained by an anxiolytic effect,
but the lack of strong correlations between baseline startle
and state measures of anxiety and sedation may point to
sources of variation that were not under control. The
complexity of the design with respect to the simple threat/
safe manipulation in the previous study may have intro-
duced additional variation. However, additional analyses on
the data from Grillon et al. (2006) indicated that even
though there were no correlations between baseline EMG
and measures of anxiety and sedation for diphenhydramine
or the low dose of alprazolam, these correlations were very
significant in the high dose of alprazolam compared to
placebo. As in our previous study, reductions in anxiety in
Grillon et al. (2006) accounted for the largest part of
variation in baseline startle (correlation r=0.68, p<0.01,
Beta in regression model=0.61, t=3.3, p<0.01), and
sedation measures accounted for some variation (marginally
significant, correlation r=0.50, p=0.07, Beta in regression
model=−0.41, t=−2.2, p=0.05). These results make it
unlikely that complexity of the design in the present study
with respect to our previous work (Baas et al. 2002a) can
explain the lack of correlations between these measures in
the present study.
These relatively weak associations between physiologi-
cal and subjective data stand in contrast with the finding
that alprazolam significantly reduced subjective ratings of
contextual fearfulness. These results were rather similar in
pattern to the effects on startle (significant reduction in
overall startle/fearfulness with a marginally significant
interaction with context), while usually, the FPS measures
prove more sensitive than subjective ratings (Grillon et al.
2006; Grillon et al. 2007). This may indicate that variability
in physiological data between subjects and sessions caused
by factors that remain unexplained resulted in low power to
detect effects of drugs on FPS in this study. If this
explanation is correct, it appears that subtle differences in
experimental conditions have a large impact on the
sensitivity of the FPS paradigm to anxiolytic drugs. In this
respect, it could be important that the study was performed
in a clinical pharmacological rather than a psychological
research institute—albeit under direct supervision of an
experienced psychophysiologist under highly controlled
circumstances. This research environment was a planned
part of the more general validation of the FPS procedure to
examine the applicability of this anxiety model for early
drug development. Marked sensitivity to changing circum-
stances would disqualify a model for regulatory purposes. It
would be important to identify and control the most
important influential methodological factors before FPS
can be considered a useful tool for anxiolytic drug
development.
The lack of effect from pregabalin on any of the
measures taken in the FPS experiment may possibly be
related to the timing of the experiment. On pregabalin,
subjects displayed a steady decline in state anxiety, which
peaked around 4–6 h after dosing while theoretically,
plasma concentrations peaked earlier (see “Methods”
section). This effect had not yet reached significance at
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45 min after dosing, between which the FPS test took place
(data will be reported elsewhere). Though state anxiety
under pregabalin was not yet significantly reduced with
respect to baseline at the 1 h 45 min measurement, decrease
of state anxiety under pregabalin compared to placebo
showed a significant correlation with decreases in baseline
startle from placebo to pregabalin. Therefore, some anxio-
lytic features were observed, but the peak of pregabalin’s
effect on state anxiety occurred well after the FPS measure-
ments took place. A negative finding in a drug study in
which the efficacy is measured at only one time point after
drug administration leaves open the possibility that the
effects were not measured at the peak of the drug’s effect in
the central nervous system. This is especially problematic
in the study of drugs of which the pharmacokinetics are still
largely unknown, as is the case in early screening of new
drugs. The FPS model could gain usability if it could be
tested at several moments after drug administration. This
would require frequent repetition of the FPS model,
including several measurements per test session after drug
administration on several different study occasions to allow
full cross-over comparative designs of different doses or
treatments. We have recently developed such a design
(Klumpers et al. 2009).
Finally, the present results again showed that diphenhy-
dramine can be used as a sedative control substance for FPS
validation studies with benzodiazepines. Nevertheless, the
problem remains that effects of sedation and anxiolysis are
hard to disentangle. Ideally, new anxiolytic drugs should
not suffer from sedative side effects. Future validation
studies would benefit from inclusion of non-sedative
anxiolytic substances. To better understand GABA-ergic
effects in human FPS models, examination of novel
subtype-selective GABA-agonists would be useful. These
experimental drugs selectively activate the α2-subunit of
the GABAA receptor, which is thought to be responsible for
the anxiolytic effects of benzodiazepines (Low et al. 2000),
without having affinity for the α1-subunit considered to be
responsible for the sedative effects (Rudolph et al. 1999).
Recent publications suggest that the availability of such
substances may not be too far ahead in the future (Atack et
al. 2006; de Haas et al. 2007; de Haas et al. 2008).
How do the mixed results in validating the fear-
potentiated startle paradigm pharmacologically compare to
validation of other human experimental models for anxiety?
Besides the FPS model, three other human experimental
models for anxiety have been subjected to repeated
attempts at pharmacological validation. Conditioned skin
conductance responses are affected by benzodiazepines, but
mostly because overall responses are subject to dampening
by drug treatments (Hellewell et al. 1999, see also Graeff et
al. 2003). Significantly reduced conditioned responses may
therefore be caused by floor effects. Even though baseline
startle is also affected by drug manipulations, the reflex
remains strong enough to avoid floor effects (Davis et al.
1993). A more recent study of conditioned fear using fear-
potentiated startle as a read-out measure did not find an
effect of diazepam on the expression of conditioned fear
(Scaife et al. 2005).
Models of social stress such as public speaking have
also been studied with mixed results. Benzodiazepines
reduce overall anxiety but do not affect the increase in
anxiety as a result of the challenge, and effects of
serotonergic manipulations are varied (see Graeff et al.
2003). The Trier social stress test showed significant
effects of alprazolam in blunting endocrine stress reac-
tions, without effects on psychological measures (Fries et
al. 2006). A drawback with tests as these is that subjects’
response habituation prevents their use in cross-over
designs (Klumpers et al. 2009).
A model proposed by Bailey et al. (2005) based on
anxiety induction by inhalation of CO2 was subjected to
pharmacological validation in several recent studies. Inha-
lation of low CO2 concentrations (7.5%) has been proposed
as a model for generalized anxiety (Bailey et al. 2005).
Benzodiazepines lorazepam (2 mg) and alprazolam (1 mg)
reduced subjective but not cardiovascular effects while
paroxetine had little effect (Bailey et al. 2007, 2009), and
propanolol, hydroxyzine, and flupentixol had no subjective
effects even though propanolol decreased heart rate
(Papadopoulos et al. 2008).
In conclusion, the present study could not confirm the
dissociationfound ineffectsof alprazolam oncontextual fear
but not cued fear. The one obvious conclusion to be drawn
from these results is that the FPS model, as is the case with
pharmacological validation of experimental models for
anxiety in general, is by no means easily implemented and
validated. Recommendations for future FPS studies are
inclusion of a baseline measurement as part of the screening
to exclude subjectswho do notdisplay FPS, which is after all
the measure of interest. The model would benefit from
further development in order to reduce variance in the startle
response and FPS. Also, models including multiple measure-
ments spread out over time would improve chances of
finding effects of a drug manipulation, especially with drugs
of which the pharmacokinetic profile is still unknown.
Finally, possible effects of the length of the interval between
startle stimuli deserve further investigation.
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